Artal Group S.A. - XILIO THERAPEUTICS INC ownership

Quarter-by-quarter ownership
Artal Group S.A. ownership history of XILIO THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$950
-19.4%
450,0000.0%0.04%
+10.8%
Q2 2023$1,179
-17.4%
450,0000.0%0.04%
-56.5%
Q1 2023$1,427
+17.8%
450,0000.0%0.08%
+25.0%
Q4 2022$1,211
-99.9%
450,0000.0%0.07%
+21.4%
Q3 2022$1,310,000
-0.3%
450,0000.0%0.06%
-20.0%
Q2 2022$1,314,000
-58.7%
450,0000.0%0.07%
-47.4%
Q1 2022$3,182,000
-55.8%
450,0000.0%0.13%
-31.8%
Q4 2021$7,200,000450,0000.20%
Other shareholders
XILIO THERAPEUTICS INC shareholders Q4 2023
NameSharesValueWeighting ↓
RiverVest Venture Management LLC 1,441,444$3,041,4477.52%
Trustees of Columbia University in the City of New York 249,635$526,7300.97%
Atlas Venture Life Science Advisors, LLC 2,759,344$5,822,2160.90%
Octagon Capital Advisors LP 2,318,500$4,892,0350.75%
Bain Capital Life Sciences Investors, LLC 2,805,413$5,919,4210.66%
HARVARD MANAGEMENT CO INC 416,059$8780.10%
Rock Springs Capital Management LP 1,440,759$3,040,0010.08%
Soleus Capital Management, L.P. 226,941$478,8460.04%
Artal Group S.A. 450,000$9500.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 110,481$233,1150.01%
View complete list of XILIO THERAPEUTICS INC shareholders